210 related articles for article (PubMed ID: 22547931)
1. Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).
Hooper CY; Smith WJ
Ther Clin Risk Manag; 2012; 8():131-7. PubMed ID: 22547931
[TBL] [Abstract][Full Text] [Related]
2. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.
Das B; Sarkar C; Das D; Gupta A; Kalra A; Sahni S
Ther Adv Infect Dis; 2017 Mar; 4(2):49-73. PubMed ID: 28634536
[TBL] [Abstract][Full Text] [Related]
3. Telavancin: a new lipoglycopeptide for gram-positive infections.
Smith WJ; Drew RH
Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
[TBL] [Abstract][Full Text] [Related]
4. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
5. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
6. Telavancin: TD 6424, TD-6424.
Drugs R D; 2006; 7(6):384-8. PubMed ID: 17073522
[TBL] [Abstract][Full Text] [Related]
7. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).
Dunbar LM; Tang DM; Manausa RM
Ther Clin Risk Manag; 2008 Feb; 4(1):235-44. PubMed ID: 18728713
[TBL] [Abstract][Full Text] [Related]
8. Telavancin: a novel lipoglycopeptide antimicrobial agent.
Attwood RJ; LaPlante KL
Am J Health Syst Pharm; 2007 Nov; 64(22):2335-48. PubMed ID: 17989443
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
Hegde SS; Janc JW
Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
[TBL] [Abstract][Full Text] [Related]
10. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
11. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
[TBL] [Abstract][Full Text] [Related]
12. Telavancin: a review of its use in patients with nosocomial pneumonia.
Scott LJ
Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
[TBL] [Abstract][Full Text] [Related]
13. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
Ruggero MA; Peaper DR; Topal JE
Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
[TBL] [Abstract][Full Text] [Related]
14. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
Polyzos KA; Mavros MN; Vardakas KZ; Makris MC; Rafailidis PI; Falagas ME
PLoS One; 2012; 7(8):e41870. PubMed ID: 22916113
[TBL] [Abstract][Full Text] [Related]
16. The role of telavancin in the treatment of MRSA infections in hospital.
Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
[TBL] [Abstract][Full Text] [Related]
17. Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections.
Jafari Saraf L; Wilson SE
Infect Drug Resist; 2011; 4():87-95. PubMed ID: 21694912
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
Adamantia L; Antoni T
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
[TBL] [Abstract][Full Text] [Related]
19. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
Leonard SN; Rybak MJ
Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
[TBL] [Abstract][Full Text] [Related]
20. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
